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Introduction
Secondary hyperparathyroidism is a common complication
for patients with end-stage renal disease (ESRD). When it
progresses,itisassociatedwithmorbidityandmortality[1].
Phosphate binders and vitamin Dcan be used toprevent the
progression of secondary hyperparathyroidism. However,
these conservative treatments often fail to control severe
hyperparathyroidism. In such cases, parathyroidectomy is
required.Despitemedicalmanagementafterparathyroidec-
tomy, persistent or recurrent hyperparathyroidism can oc-
cur. One of the causes of recurrent hyperparathyroidism
is parathyromatosis, which has been described as multi-
ple nodules or rests of hyperfunctioning parathyroid tissue
that become evident following parathyroidectomy. We de-
scribe a female haemodialysis patient diagnosed with sec-
ondary hyperparathyroidism, which was probably caused
by parathyromatosis. Treatment with cinacalcet, a cal-
cimimetic agent, in combination with vitamin D was ex-
tremely effective.
Case report
A 66-year-old woman with ESRD due to chronic glomeru-
lonephritis was started on haemodialysis therapy in
April 1992 at the age of 50. In October 1997, she was diag-
nosed with secondary hyperparathyroidism after her serum
parathyroid hormone (PTH) level reached 940 pg/ml. The
serum calcium level was 10.5 mg/dl, the serum phospho-
rus level was 4.8 mg/dl and the alkaline phosphatase level
was 502 IU/l. Conservative oral vitamin D therapy was
started. In April 2000, three enlarged parathyroid glands
werefound.Specifically,therightinferiorglandwas18mm
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in diameter, the left superior gland was 17 mm and the
left inferior gland was 19 mm by ultrasonography (US).
Parathyroidectomy with autotransplantation of tissue into
the left forearm was performed. The right and left infe-
rior glands were easily removed, but the left superior gland
was in the thyroid lobe. The right superior gland could not
be detected. The pathological diagnosis of all the enlarged
glands was nodular parathyroid hyperplasia.
Unfortunately, the int-PTH level continued to increase
and reached 2160 pg/ml in April 2001. Considering the
results of CT and technetium Tc 99m-sestamibi scans, re-
movaloftheremainingglandwasperformed.Theglandwas
located in the right fossa supraclavicularis with attachment
to the back of the trachea. Although we removed as much
of the gland as possible, the patient had persistent paresis
of the right recurrent laryngeal nerve postoperatively. In
June 2003, she fell down and fractured her femoral neck.
In August 2003, enlargement of the autografted parathy-
roidtissuesinherleftforearmwasdetected,andtheint-PTH
levelwas1800pg/ml.Sincetheautograftedparathyroidtis-
sues were considered to be one of the main sources of PTH,
they were removed. After the operation, the int-PTH level
decreased to 290 pg/ml, but gradually increased thereafter.
In August 2004 and November 2005, operations to remove
the autografted parathyroid tissues were performed again.
However, these operations were unsuccessful and the int-
PTH levels were around 700 pg/ml.
In November 2006, the origins of her PTH oversecre-
tion were re-evaluated. Autografted parathyroid nodules in
the left forearm were detected by MRI, while nodules lo-
cated around the bilateral lower poles of the thyroid lobes
weredetectedbytechnetiumTc99m-sestamibi,CTandUS
scans. Considering the risk of bilateral paresis of the recur-
rent laryngeal nerve, we were hesitant to re-operate. The
possibility of parathyromatosis due to dissemination of the
parathyroid tissue during the previous parathyroidectomy
was considered. Histological examinations until this time
showed no evidence of malignancy.
The dosage of calcitriol was limited to 3 µg/week due
to hypercalcemia, and failed to stop the int-PTH level from
reaching 1880 pg/ml. The patient was troubled by pruritus
and bone pain in various parts of her body.
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Fig. 1. Calcium, phosphorus and int-PTH levels during treatment with cinacalcet.
In December 2006, we started to administer cinacal-
cet using a dosage of 30 mg/day, in addition to a phos-
phatebinder(sevelamer4.5g/day)andvitaminD(calcitriol
3 µg/week intravenously). At 3 months after initiation of
the therapy, we increased the cinacalcet dose to 60 mg/day,
and its effects were more remarkable. The int-PTH level
gradually decreased to 100–200 pg/ml, and the levels of
serum calcium and phosphorus normalized (Figure 1). Af-
ter the treatment, her severe bone pain disappeared, and the
pruritus was relieved.
Her bone mineral density (BMD) was improved by ad-
ministration of cinacalcet. Before the treatment, the BMD
of the distal one-third of the radial bone by dual-energy
X-ray absorptiometry (DEXA) was 0.248 g/cm2 (T score,
−7.62 SD), but after 1.4 years of administration of cinacal-
cet,itbecame0.286g/cm2 (Tscore,−6.92SD).Thechange
in the BMD was 11.1% per year. The alkaline phosphatase
level decreased from 1459 to 443 IU/l, while bone-type al-
kaline phosphatase (BAP) changed from 239 to 39 U/l and
type 1 collagen N-telopeptide (NTX) changed from 800 to
62.5 nmol/BCE/l (Figure 2). It has currently been 16 years
since she started haemodialysis, but she can now visit our
hospital unaccompanied without using a wheelchair and
without any pain or any additional bone fractures.
Discussion
Parathyromatosis is an uncommon but important cause of
recurrent hyperparathyroidism. Two forms of parathyro-
matosis have been reported. Primary or type 1 parathy-
romatosis is thought to be due to hyperplasia of parathy-
roid rests from embryologic development [2]. The more
common type 2 parathyromatosis occurs after spillage and
seeding of parathyroid tissue during parathyroid resection
[2,3]. The present case is considered to be due to the lat-
ter situation. Parathyromatosis is difficult both to diagnose
postoperatively, and to completely control by re-operations
[4].
There are two previous reports regarding the success-
ful use of cinacalcet for treating parathyromastosis [5,6].
In our case, the calcium, phosphorous and int-PTH levels
couldbecontrolledwithintheNKF-K/DOQIrecommended
targets for long periods, and her BMD was remarkably
improved. Cinacalcet reduces PTH production and secre-
tion by increasing the sensitivity of calcium-sensing recep-
tors (CaSRs) to extracellular calcium. Activation of CaSRs
not only reduces hormone secretion but also decreases
parathyroid cell proliferation [7]. In our case, the severe
hyperparathyroidism may not be due to parathyromatosis
alone, and other possible causes were inoperable residual
parathyroid glands or relapse of autografted parathyroid
glands. Regardless of the cause, our patient clearly had
nodular parathyroid hyperplasia considering the sizes of
the parathyroid glands and the histological results. Cells
in nodular hyperplasia have reduced numbers of vitamin
D receptors and CaSRs, and are thus usually refractory to
medical therapies [8]. Our present findings suggest that ad-
ministration of cinacalcet with vitamin D may be effective
against nodular hyperplasia.
Moreover, even though our patient had low BMD due
to severe secondary hyperparathyroidism, her BMD im-
proved after treatment with cinacalcet and vitamin D. This
effect can lead to elimination of bone pain and prevention
of additional bone fractures. Lien reported that cinacalcet
reversed bone loss in the proximal femur, but did not affect
the BMD of the lumbar spine [9]. Although our patient had
extremely low BMD of the radial bone compared to this220 R. Eriguchi et al.
Fig. 2. Top: levels of int-PTH (pg/ml), type 1 collagen N-telopeptide (NTX; nmol/BCE/l) and bone-type alkaline phosphatase (BAP; U/l) before and
during treatment with cinacalcet. Bottom: bone mineral density (BMD) before and during treatment with cinacalcet.
previous study based on T scores, her BMD nevertheless
improved.
Rothe reported on a CaSR gene polymorphism,
Arg990Gly, and its possible effects on the response to
cinacalcet [10]. Homogeneous patients for the Arg990Gly
polymorphism showed significantly higher sensitivities to
cinacalcet with reduced int-PTH levels from the baseline.
Ourpatientwasexaminedforthisgenepolymorphismafter
providing an informed consent. She was found to be het-
erozygous for the Arg990Gly polymorphism, but the effect
of cinacalcet was very evident.
In conclusion, cinacalcet is effective for refractory and
inoperable secondary hyperparathyroidism patients. In ad-
dition, it improves their BMD and relieves bone pain.
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